PharmaLex Group, a global service provider for the pharma, biotech and medtech industries has announced the opening of a new branch in Beijing, China, giving global clients access to a team of regulatory experts in the region.

As of September 2022, the newly established PharmaLex Beijing team, which includes personnel joining from Bayer China, will be offering the full PharmaLex value proposition for pharmacovigilance, regulatory affairs, development consulting and quality management to global clients bringing products to the China market.

PharmaLex China will also be the local contact point for Chinese-based biopharmaceutical companies that are developing pharmaceuticals or medical devices with a goal of entering the European or US markets.

In addition, Pharmalex is preparing to open a second China office in Jinan (China), which will extend the local footprint and provide clients with further access to a regulatory talent pool in the country. 

The China office will be led by Sophia Huang, Executive Director and Department Head accompanied by 16 highly skilled regulatory submission and publishing experts.